Global Immune-mediated Necrotizing Myopathy Treatment Market Growth (Status and Outlook) 2026-2032
The global Immune-mediated Necrotizing Myopathy Treatment market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Immune-mediated necrotizing myopathy (IMNM) is a rare autoimmune muscle disease characterized by muscle inflammation and weakness. Treatment for immune-mediated necrotizing myopathy typically involves immunosuppressive therapies aimed at modulating or suppressing the immune response to reduce muscle inflammation and prevent further damage.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the ?Immune-mediated Necrotizing Myopathy Treatment Industry Forecast? looks at past sales and reviews total world Immune-mediated Necrotizing Myopathy Treatment sales in 2025, providing a comprehensive analysis by region and market sector of projected Immune-mediated Necrotizing Myopathy Treatment sales for 2026 through 2032. With Immune-mediated Necrotizing Myopathy Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immune-mediated Necrotizing Myopathy Treatment industry.
This Insight Report provides a comprehensive analysis of the global Immune-mediated Necrotizing Myopathy Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Immune-mediated Necrotizing Myopathy Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Immune-mediated Necrotizing Myopathy Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immune-mediated Necrotizing Myopathy Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immune-mediated Necrotizing Myopathy Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Immune-mediated Necrotizing Myopathy Treatment market by product type, application, key players and key regions and countries.
Segmentation by Type:
Immune-mediated necrotizing myopathy (IMNM) is a rare autoimmune muscle disease characterized by muscle inflammation and weakness. Treatment for immune-mediated necrotizing myopathy typically involves immunosuppressive therapies aimed at modulating or suppressing the immune response to reduce muscle inflammation and prevent further damage.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the ?Immune-mediated Necrotizing Myopathy Treatment Industry Forecast? looks at past sales and reviews total world Immune-mediated Necrotizing Myopathy Treatment sales in 2025, providing a comprehensive analysis by region and market sector of projected Immune-mediated Necrotizing Myopathy Treatment sales for 2026 through 2032. With Immune-mediated Necrotizing Myopathy Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immune-mediated Necrotizing Myopathy Treatment industry.
This Insight Report provides a comprehensive analysis of the global Immune-mediated Necrotizing Myopathy Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Immune-mediated Necrotizing Myopathy Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Immune-mediated Necrotizing Myopathy Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immune-mediated Necrotizing Myopathy Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immune-mediated Necrotizing Myopathy Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Immune-mediated Necrotizing Myopathy Treatment market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Steroids
- Immunosuppressant
- Others
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GlaxoSmithKline plc
- Dr. Reddy's Laboratories
- Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
- Hetero Drugs Limited
- AbbVie Inc.
- Teva Pharmaceutical Industries
- Novartis AG
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immune-mediated Necrotizing Myopathy Treatment Market Size (2021-2032)
2.1.2 Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Immune-mediated Necrotizing Myopathy Treatment by Country/Region (2021, 2025 & 2032)
2.2 Immune-mediated Necrotizing Myopathy Treatment Segment by Type
2.2.1 Steroids
2.2.2 Immunosuppressant
2.2.3 Others
2.2.4 Immune-mediated Necrotizing Myopathy Treatment Market Size by Type
2.2.4.1 Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2021-2026)
2.3 Immune-mediated Necrotizing Myopathy Treatment Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Others
2.3.4 Immune-mediated Necrotizing Myopathy Treatment Market Size by Application
2.3.4.1 Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2021-2026)
3 IMMUNE-MEDIATED NECROTIZING MYOPATHY TREATMENT MARKET SIZE BY PLAYER
3.1 Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Player
3.1.1 Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Player (2021-2026)
3.1.2 Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Player (2021-2026)
3.2 Global Immune-mediated Necrotizing Myopathy Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 IMMUNE-MEDIATED NECROTIZING MYOPATHY TREATMENT BY REGION
4.1 Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2021-2026)
4.2 Global Immune-mediated Necrotizing Myopathy Treatment Annual Revenue by Country/Region (2021-2026)
4.3 Americas Immune-mediated Necrotizing Myopathy Treatment Market Size Growth (2021-2026)
4.4 APAC Immune-mediated Necrotizing Myopathy Treatment Market Size Growth (2021-2026)
4.5 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Growth (2021-2026)
4.6 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2021-2026)
5.2 Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026)
5.3 Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2021-2026)
6.2 APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026)
6.3 APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2021-2026)
7.2 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026)
7.3 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment by Region (2021-2026)
8.2 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026)
8.3 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL IMMUNE-MEDIATED NECROTIZING MYOPATHY TREATMENT MARKET FORECAST
10.1 Global Immune-mediated Necrotizing Myopathy Treatment Forecast by Region (2027-2032)
10.1.1 Global Immune-mediated Necrotizing Myopathy Treatment Forecast by Region (2027-2032)
10.1.2 Americas Immune-mediated Necrotizing Myopathy Treatment Forecast
10.1.3 APAC Immune-mediated Necrotizing Myopathy Treatment Forecast
10.1.4 Europe Immune-mediated Necrotizing Myopathy Treatment Forecast
10.1.5 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Forecast
10.2 Americas Immune-mediated Necrotizing Myopathy Treatment Forecast by Country (2027-2032)
10.2.1 United States Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.2.2 Canada Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.2.3 Mexico Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.2.4 Brazil Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.3 APAC Immune-mediated Necrotizing Myopathy Treatment Forecast by Region (2027-2032)
10.3.1 China Immune-mediated Necrotizing Myopathy Treatment Market Forecast
10.3.2 Japan Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.3.3 Korea Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.3.4 Southeast Asia Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.3.5 India Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.3.6 Australia Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.4 Europe Immune-mediated Necrotizing Myopathy Treatment Forecast by Country (2027-2032)
10.4.1 Germany Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.4.2 France Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.4.3 UK Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.4.4 Italy Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.4.5 Russia Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.5 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Forecast by Region (2027-2032)
10.5.1 Egypt Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.5.2 South Africa Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.5.3 Israel Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.5.4 Turkey Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.6 Global Immune-mediated Necrotizing Myopathy Treatment Forecast by Type (2027-2032)
10.7 Global Immune-mediated Necrotizing Myopathy Treatment Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Immune-mediated Necrotizing Myopathy Treatment Forecast
11 KEY PLAYERS ANALYSIS
11.1 GlaxoSmithKline plc
11.1.1 GlaxoSmithKline plc Company Information
11.1.2 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.1.3 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 GlaxoSmithKline plc Main Business Overview
11.1.5 GlaxoSmithKline plc Latest Developments
11.2 Dr. Reddy's Laboratories
11.2.1 Dr. Reddy's Laboratories Company Information
11.2.2 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.2.3 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Dr. Reddy's Laboratories Main Business Overview
11.2.5 Dr. Reddy's Laboratories Latest Developments
11.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
11.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Information
11.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Main Business Overview
11.3.5 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Latest Developments
11.4 Hetero Drugs Limited
11.4.1 Hetero Drugs Limited Company Information
11.4.2 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.4.3 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Hetero Drugs Limited Main Business Overview
11.4.5 Hetero Drugs Limited Latest Developments
11.5 AbbVie Inc.
11.5.1 AbbVie Inc. Company Information
11.5.2 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.5.3 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 AbbVie Inc. Main Business Overview
11.5.5 AbbVie Inc. Latest Developments
11.6 Teva Pharmaceutical Industries
11.6.1 Teva Pharmaceutical Industries Company Information
11.6.2 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.6.3 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Teva Pharmaceutical Industries Main Business Overview
11.6.5 Teva Pharmaceutical Industries Latest Developments
11.7 Novartis AG
11.7.1 Novartis AG Company Information
11.7.2 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.7.3 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Novartis AG Main Business Overview
11.7.5 Novartis AG Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immune-mediated Necrotizing Myopathy Treatment Market Size (2021-2032)
2.1.2 Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Immune-mediated Necrotizing Myopathy Treatment by Country/Region (2021, 2025 & 2032)
2.2 Immune-mediated Necrotizing Myopathy Treatment Segment by Type
2.2.1 Steroids
2.2.2 Immunosuppressant
2.2.3 Others
2.2.4 Immune-mediated Necrotizing Myopathy Treatment Market Size by Type
2.2.4.1 Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2021-2026)
2.3 Immune-mediated Necrotizing Myopathy Treatment Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Others
2.3.4 Immune-mediated Necrotizing Myopathy Treatment Market Size by Application
2.3.4.1 Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2021-2026)
3 IMMUNE-MEDIATED NECROTIZING MYOPATHY TREATMENT MARKET SIZE BY PLAYER
3.1 Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Player
3.1.1 Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Player (2021-2026)
3.1.2 Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Player (2021-2026)
3.2 Global Immune-mediated Necrotizing Myopathy Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 IMMUNE-MEDIATED NECROTIZING MYOPATHY TREATMENT BY REGION
4.1 Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2021-2026)
4.2 Global Immune-mediated Necrotizing Myopathy Treatment Annual Revenue by Country/Region (2021-2026)
4.3 Americas Immune-mediated Necrotizing Myopathy Treatment Market Size Growth (2021-2026)
4.4 APAC Immune-mediated Necrotizing Myopathy Treatment Market Size Growth (2021-2026)
4.5 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Growth (2021-2026)
4.6 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2021-2026)
5.2 Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026)
5.3 Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2021-2026)
6.2 APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026)
6.3 APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2021-2026)
7.2 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026)
7.3 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment by Region (2021-2026)
8.2 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026)
8.3 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL IMMUNE-MEDIATED NECROTIZING MYOPATHY TREATMENT MARKET FORECAST
10.1 Global Immune-mediated Necrotizing Myopathy Treatment Forecast by Region (2027-2032)
10.1.1 Global Immune-mediated Necrotizing Myopathy Treatment Forecast by Region (2027-2032)
10.1.2 Americas Immune-mediated Necrotizing Myopathy Treatment Forecast
10.1.3 APAC Immune-mediated Necrotizing Myopathy Treatment Forecast
10.1.4 Europe Immune-mediated Necrotizing Myopathy Treatment Forecast
10.1.5 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Forecast
10.2 Americas Immune-mediated Necrotizing Myopathy Treatment Forecast by Country (2027-2032)
10.2.1 United States Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.2.2 Canada Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.2.3 Mexico Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.2.4 Brazil Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.3 APAC Immune-mediated Necrotizing Myopathy Treatment Forecast by Region (2027-2032)
10.3.1 China Immune-mediated Necrotizing Myopathy Treatment Market Forecast
10.3.2 Japan Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.3.3 Korea Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.3.4 Southeast Asia Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.3.5 India Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.3.6 Australia Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.4 Europe Immune-mediated Necrotizing Myopathy Treatment Forecast by Country (2027-2032)
10.4.1 Germany Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.4.2 France Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.4.3 UK Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.4.4 Italy Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.4.5 Russia Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.5 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Forecast by Region (2027-2032)
10.5.1 Egypt Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.5.2 South Africa Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.5.3 Israel Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.5.4 Turkey Market Immune-mediated Necrotizing Myopathy Treatment Forecast
10.6 Global Immune-mediated Necrotizing Myopathy Treatment Forecast by Type (2027-2032)
10.7 Global Immune-mediated Necrotizing Myopathy Treatment Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Immune-mediated Necrotizing Myopathy Treatment Forecast
11 KEY PLAYERS ANALYSIS
11.1 GlaxoSmithKline plc
11.1.1 GlaxoSmithKline plc Company Information
11.1.2 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.1.3 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 GlaxoSmithKline plc Main Business Overview
11.1.5 GlaxoSmithKline plc Latest Developments
11.2 Dr. Reddy's Laboratories
11.2.1 Dr. Reddy's Laboratories Company Information
11.2.2 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.2.3 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Dr. Reddy's Laboratories Main Business Overview
11.2.5 Dr. Reddy's Laboratories Latest Developments
11.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
11.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Information
11.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Main Business Overview
11.3.5 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Latest Developments
11.4 Hetero Drugs Limited
11.4.1 Hetero Drugs Limited Company Information
11.4.2 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.4.3 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Hetero Drugs Limited Main Business Overview
11.4.5 Hetero Drugs Limited Latest Developments
11.5 AbbVie Inc.
11.5.1 AbbVie Inc. Company Information
11.5.2 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.5.3 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 AbbVie Inc. Main Business Overview
11.5.5 AbbVie Inc. Latest Developments
11.6 Teva Pharmaceutical Industries
11.6.1 Teva Pharmaceutical Industries Company Information
11.6.2 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.6.3 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Teva Pharmaceutical Industries Main Business Overview
11.6.5 Teva Pharmaceutical Industries Latest Developments
11.7 Novartis AG
11.7.1 Novartis AG Company Information
11.7.2 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Product Offered
11.7.3 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Novartis AG Main Business Overview
11.7.5 Novartis AG Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Immune-mediated Necrotizing Myopathy Treatment Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Steroids
Table 4. Major Players of Immunosuppressant
Table 5. Major Players of Others
Table 6. Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2021-2026)
Table 9. Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026) & ($ millions)
Table 11. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2021-2026)
Table 12. Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Player (2021-2026) & ($ millions)
Table 13. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Player (2021-2026)
Table 14. Immune-mediated Necrotizing Myopathy Treatment Key Players Head office and Products Offered
Table 15. Immune-mediated Necrotizing Myopathy Treatment Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2021-2026) & ($ millions)
Table 19. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Region (2021-2026)
Table 20. Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Country (2021-2026)
Table 24. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2021-2026)
Table 26. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2021-2026)
Table 28. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Region (2021-2026)
Table 30. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Country (2021-2026)
Table 34. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Immune-mediated Necrotizing Myopathy Treatment
Table 40. Key Market Challenges & Risks of Immune-mediated Necrotizing Myopathy Treatment
Table 41. Key Industry Trends of Immune-mediated Necrotizing Myopathy Treatment
Table 42. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. GlaxoSmithKline plc Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 47. GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 48. GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. GlaxoSmithKline plc Main Business
Table 50. GlaxoSmithKline plc Latest Developments
Table 51. Dr. Reddy's Laboratories Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 52. Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 53. Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Dr. Reddy's Laboratories Main Business
Table 55. Dr. Reddy's Laboratories Latest Developments
Table 56. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 57. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 58. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Main Business
Table 60. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Latest Developments
Table 61. Hetero Drugs Limited Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 62. Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 63. Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Hetero Drugs Limited Main Business
Table 65. Hetero Drugs Limited Latest Developments
Table 66. AbbVie Inc. Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 67. AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 68. AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. AbbVie Inc. Main Business
Table 70. AbbVie Inc. Latest Developments
Table 71. Teva Pharmaceutical Industries Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 72. Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 73. Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Teva Pharmaceutical Industries Main Business
Table 75. Teva Pharmaceutical Industries Latest Developments
Table 76. Novartis AG Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 77. Novartis AG Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 78. Novartis AG Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Novartis AG Main Business
Table 80. Novartis AG Latest Developments
Table 1. Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Immune-mediated Necrotizing Myopathy Treatment Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Steroids
Table 4. Major Players of Immunosuppressant
Table 5. Major Players of Others
Table 6. Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2021-2026)
Table 9. Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026) & ($ millions)
Table 11. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2021-2026)
Table 12. Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Player (2021-2026) & ($ millions)
Table 13. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Player (2021-2026)
Table 14. Immune-mediated Necrotizing Myopathy Treatment Key Players Head office and Products Offered
Table 15. Immune-mediated Necrotizing Myopathy Treatment Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2021-2026) & ($ millions)
Table 19. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Region (2021-2026)
Table 20. Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Country (2021-2026)
Table 24. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2021-2026)
Table 26. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2021-2026)
Table 28. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Region (2021-2026)
Table 30. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Country (2021-2026)
Table 34. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Immune-mediated Necrotizing Myopathy Treatment
Table 40. Key Market Challenges & Risks of Immune-mediated Necrotizing Myopathy Treatment
Table 41. Key Industry Trends of Immune-mediated Necrotizing Myopathy Treatment
Table 42. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. GlaxoSmithKline plc Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 47. GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 48. GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. GlaxoSmithKline plc Main Business
Table 50. GlaxoSmithKline plc Latest Developments
Table 51. Dr. Reddy's Laboratories Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 52. Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 53. Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Dr. Reddy's Laboratories Main Business
Table 55. Dr. Reddy's Laboratories Latest Developments
Table 56. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 57. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 58. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Main Business
Table 60. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Latest Developments
Table 61. Hetero Drugs Limited Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 62. Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 63. Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Hetero Drugs Limited Main Business
Table 65. Hetero Drugs Limited Latest Developments
Table 66. AbbVie Inc. Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 67. AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 68. AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. AbbVie Inc. Main Business
Table 70. AbbVie Inc. Latest Developments
Table 71. Teva Pharmaceutical Industries Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 72. Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 73. Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Teva Pharmaceutical Industries Main Business
Table 75. Teva Pharmaceutical Industries Latest Developments
Table 76. Novartis AG Details, Company Type, Immune-mediated Necrotizing Myopathy Treatment Area Served and Its Competitors
Table 77. Novartis AG Immune-mediated Necrotizing Myopathy Treatment Product Offered
Table 78. Novartis AG Immune-mediated Necrotizing Myopathy Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Novartis AG Main Business
Table 80. Novartis AG Latest Developments
LIST OF FIGURES
Figure 1. Immune-mediated Necrotizing Myopathy Treatment Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Immune-mediated Necrotizing Myopathy Treatment Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Immune-mediated Necrotizing Myopathy Treatment Sales Market Share by Country/Region (2025)
Figure 8. Immune-mediated Necrotizing Myopathy Treatment Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type in 2025
Figure 10. Immune-mediated Necrotizing Myopathy Treatment in Hospital
Figure 11. Global Immune-mediated Necrotizing Myopathy Treatment Market: Hospital (2021-2026) & ($ millions)
Figure 12. Immune-mediated Necrotizing Myopathy Treatment in Clinic
Figure 13. Global Immune-mediated Necrotizing Myopathy Treatment Market: Clinic (2021-2026) & ($ millions)
Figure 14. Immune-mediated Necrotizing Myopathy Treatment in Others
Figure 15. Global Immune-mediated Necrotizing Myopathy Treatment Market: Others (2021-2026) & ($ millions)
Figure 16. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application in 2025
Figure 17. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Player in 2025
Figure 18. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Region (2021-2026)
Figure 19. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size 2021-2026 ($ millions)
Figure 20. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size 2021-2026 ($ millions)
Figure 21. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size 2021-2026 ($ millions)
Figure 23. Americas Immune-mediated Necrotizing Myopathy Treatment Value Market Share by Country in 2025
Figure 24. United States Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Region in 2025
Figure 29. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2021-2026)
Figure 30. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2021-2026)
Figure 31. China Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 35. India Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Country in 2025
Figure 38. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2021-2026)
Figure 39. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2021-2026)
Figure 40. Germany Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 41. France Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 54. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 55. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 57. United States Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 58. Canada Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 59. Mexico Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 60. Brazil Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 61. China Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 62. Japan Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 63. Korea Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 65. India Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 66. Australia Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 67. Germany Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 68. France Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 69. UK Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 70. Italy Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 71. Russia Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 72. Egypt Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 73. South Africa Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 74. Israel Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 75. Turkey Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 76. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 1. Immune-mediated Necrotizing Myopathy Treatment Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Immune-mediated Necrotizing Myopathy Treatment Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Immune-mediated Necrotizing Myopathy Treatment Sales Market Share by Country/Region (2025)
Figure 8. Immune-mediated Necrotizing Myopathy Treatment Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type in 2025
Figure 10. Immune-mediated Necrotizing Myopathy Treatment in Hospital
Figure 11. Global Immune-mediated Necrotizing Myopathy Treatment Market: Hospital (2021-2026) & ($ millions)
Figure 12. Immune-mediated Necrotizing Myopathy Treatment in Clinic
Figure 13. Global Immune-mediated Necrotizing Myopathy Treatment Market: Clinic (2021-2026) & ($ millions)
Figure 14. Immune-mediated Necrotizing Myopathy Treatment in Others
Figure 15. Global Immune-mediated Necrotizing Myopathy Treatment Market: Others (2021-2026) & ($ millions)
Figure 16. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application in 2025
Figure 17. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Player in 2025
Figure 18. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Region (2021-2026)
Figure 19. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size 2021-2026 ($ millions)
Figure 20. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size 2021-2026 ($ millions)
Figure 21. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size 2021-2026 ($ millions)
Figure 23. Americas Immune-mediated Necrotizing Myopathy Treatment Value Market Share by Country in 2025
Figure 24. United States Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Region in 2025
Figure 29. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2021-2026)
Figure 30. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2021-2026)
Figure 31. China Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 35. India Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Country in 2025
Figure 38. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2021-2026)
Figure 39. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2021-2026)
Figure 40. Germany Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 41. France Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Immune-mediated Necrotizing Myopathy Treatment Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 54. APAC Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 55. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 57. United States Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 58. Canada Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 59. Mexico Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 60. Brazil Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 61. China Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 62. Japan Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 63. Korea Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 65. India Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 66. Australia Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 67. Germany Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 68. France Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 69. UK Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 70. Italy Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 71. Russia Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 72. Egypt Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 73. South Africa Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 74. Israel Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 75. Turkey Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
Figure 76. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Immune-mediated Necrotizing Myopathy Treatment Market Size 2027-2032 ($ millions)
